VistaGen Therapeutics, Inc. EV/FCF

EV/FCF of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/FCF of VistaGen Therapeutics, Inc. is -2.69 (as of March 30, 2017)
  • EV/FCF for the quarter ending December 30, 2020 was -6.1 (a 44.21% increase compared to previous quarter)
  • Year-over-year quarterly EV/FCF decreased by -95.63%
  • Annual EV/FCF for 2017 was -2.69 (a -96.84% decrease from previous year)
  • Annual EV/FCF for 2013 was -85.13 (a -61.77% decrease from previous year)
  • Annual EV/FCF for 2012 was -222.69 (a -Infinity% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of VistaGen Therapeutics, Inc.

Most recent EV/FCFof VTGN including historical data for past 10 years.

Interactive Chart of EV/FCF of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -6.1 -4.23
2017 -2.69
2016 -4.82
2013 -85.13
2012 -139.73 -222.69 -222.69
2011 -342.72 -345.49 -314.09 0.0 0.0
2010 0.0 0.0

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.